<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7207128\results\search\disease\results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="the COVID-19 resource centre remains active. Abstract The new coronavirus" exact="infection" post="COVID-19 has quickly become a global health emergency. Mortality"/>
  <result pre="a global health emergency. Mortality is principally due to severe" exact="Acute" post="Respiratory Distress Syndrome (ARDS) which relays only on supportive"/>
  <result pre="global health emergency. Mortality is principally due to severe Acute" exact="Respiratory" post="Distress Syndrome (ARDS) which relays only on supportive treatment."/>
  <result pre="emergency. Mortality is principally due to severe Acute Respiratory Distress" exact="Syndrome" post="(ARDS) which relays only on supportive treatment. Numerous pathological,"/>
  <result pre="Etoposide-based protocol including dexametasone is the standard of care for" exact="secondary" post="HLH. The protocol has been successfully used in HLHs"/>
  <result pre="The protocol has been successfully used in HLHs that are" exact="secondary" post="to EBV and H1N1 infections by inducing complete response"/>
  <result pre="used in HLHs that are secondary to EBV and H1N1" exact="infections" post="by inducing complete response and prolonged survival. These observations"/>
  <result pre="that are secondary to EBV and H1N1 infections by inducing" exact="complete" post="response and prolonged survival. These observations prompt to consider"/>
  <result pre="is on drug development by exploring the available therapeutic possibilities." exact="Severe" post="cases are the most challenging as they may be"/>
  <result pre="most challenging as they may be complicated by a severe" exact="Acute" post="Respiratory Distress Syndrome (ARDS) [2]. The current management of"/>
  <result pre="challenging as they may be complicated by a severe Acute" exact="Respiratory" post="Distress Syndrome (ARDS) [2]. The current management of ARDS"/>
  <result pre="they may be complicated by a severe Acute Respiratory Distress" exact="Syndrome" post="(ARDS) [2]. The current management of ARDS is only"/>
  <result pre="(HIV drugs or Ebola frizzled drug) as well as promising" exact="malaria" post="drugs chloroquine and hydroxychloroquine. COVID-19 and haemophagocytic lymphohistiocytosis (HLH)"/>
  <result pre="IL-7, granulocyte colony stimulating factor, interferon-Î³ (IFN-Î³), inducible protein 10," exact="monocyte" post="chemoattractant proteinÂ 1, macrophage inflammatory protein 1-Î±, and tumour"/>
  <result pre="[4]. This up-regulation is the main characteristic of Cytokines Storm" exact="Syndromes" post="(CSS). The CSSs are associated with hemophagocytic lymphohistiocytosis (HLH)"/>
  <result pre="of Cytokines Storm Syndromes (CSS). The CSSs are associated with" exact="hemophagocytic lymphohistiocytosis" post="(HLH) which can be primary or familial (pHLH) or"/>
  <result pre="CSSs are associated with hemophagocytic lymphohistiocytosis (HLH) which can be" exact="primary" post="or familial (pHLH) or secondary, acquired or reactive (sHLH)"/>
  <result pre="associated with hemophagocytic lymphohistiocytosis (HLH) which can be primary or" exact="familial" post="(pHLH) or secondary, acquired or reactive (sHLH) [5]. The"/>
  <result pre="(HLH) which can be primary or familial (pHLH) or secondary," exact="acquired" post="or reactive (sHLH) [5]. The sHLH, occurring frequently after"/>
  <result pre="IL-2 receptor â‰¥2400Â U/mL). Five of the eight criteria in" exact="total" post="are needed to make a diagnosis of HLH (Table"/>
  <result pre="cells [10]. The latter cells may be haemophagocytes. Table 1" exact="Secondary" post="HLH diagnosis criteria. 1. Fever 2. Splenomegaly 3. Cytopenias"/>
  <result pre="may be haemophagocytes. Table 1 Secondary HLH diagnosis criteria. 1." exact="Fever" post="2. Splenomegaly 3. Cytopenias (affecting â‰¥2 of 3 lineages"/>
  <result pre="Splenomegaly 3. Cytopenias (affecting â‰¥2 of 3 lineages in the" exact="peripheral" post="blood):Â Hemoglobin &amp;lt;90Â g/L (in infants &amp;lt;4Â weeks: hemoglobin"/>
  <result pre="g/L)Â Platelets &amp;lt;100Â Ã—Â 109/LÂ Neutrophils &amp;lt;1.0Â Ã—Â 109/L 4." exact="Hypertriglyceridemia" post="and/or hypofibrinogenemia:Â Fasting triglycerides â‰¥3.0Â mmol/L (i.e., â‰¥265Â mg/dl)Â"/>
  <result pre="mg/L 8. Soluble CD25 (i.e., soluble IL-2 receptor) â‰¥2400 U/ml" exact="Secondary" post="HLH diagnosis criteria adapted from Henter et al. 2007."/>
  <result pre="criteria should be fulfilled. Even though the pathophysiology of HLH" exact="secondary" post="to an infection is still largely unclear, it is"/>
  <result pre="fulfilled. Even though the pathophysiology of HLH secondary to an" exact="infection" post="is still largely unclear, it is presumably similar to"/>
  <result pre="maintains cytokines release [11]. Interestingly, data from China suggests the" exact="viral" post="load is higher in patients with more severe disease"/>
  <result pre="the viral load is higher in patients with more severe" exact="disease" post="[12]. This may be due the persistence of the"/>
  <result pre="disease [12]. This may be due the persistence of the" exact="viral" post="insult caused by cytotoxic cells dysfunction. Clinical and laboratory"/>
  <result pre="observations made in the context of HLH development during H1N1" exact="infection" post="[13]. Hence, there are accumulating elements suggesting that moderately"/>
  <result pre="on etoposide and dexamethasone with intrathecal methotrexate in case of" exact="central nervous system" post="involvement [14], [15]. Interestingly, this treatment induced complete remissions"/>
  <result pre="central nervous system involvement [14], [15]. Interestingly, this treatment induced" exact="complete" post="remissions in moderately severe to severe sHLH associated to"/>
  <result pre="especially when it was started less than 4Â weeks from" exact="infection" post="diagnosis [16], [17], [18]. The combination has also been"/>
  <result pre="hepatitis-B-virus associated HLH [19], [20]. It is possible that the" exact="limited" post="use of this protocol in sHLH associated to other"/>
  <result pre="limited use of this protocol in sHLH associated to other" exact="viral" post="infections may be due to their rarity or to"/>
  <result pre="use of this protocol in sHLH associated to other viral" exact="infections" post="may be due to their rarity or to their"/>
  <result pre="effects that can be symptomatically treated. It may also induce" exact="secondary" post="malignancies especially acute myeloid leukaemia. This risk is estimated"/>
  <result pre="be symptomatically treated. It may also induce secondary malignancies especially" exact="acute" post="myeloid leukaemia. This risk is estimated at 0.3â€&quot;0.4% [21]."/>
  <result pre="for infection-Associated HLH [15]. The suggested therapy for patients with" exact="viral" post="infections and severe sHLH is the use of the"/>
  <result pre="infection-Associated HLH [15]. The suggested therapy for patients with viral" exact="infections" post="and severe sHLH is the use of the combination"/>
  <result pre="the work reported in this paper. References References 1WHO. Coronavirus" exact="disease" post="2019 (COVID-19) Situation Report â€&quot; 67. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200327-sitrep-67-covid-19.pdf?sfvrsn=b65f68eb_4. 2YangX.YuY.XuJ.Clinical course"/>
  <result pre="2YangX.YuY.XuJ.Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational studyLancet Respir"/>
  <result pre="retrospective, observational studyLancet Respir Med2020 3WHO. Clinical management of severe" exact="acute" post="respiratory infection when novel coronavirus (nCoV) infection is suspected."/>
  <result pre="observational studyLancet Respir Med2020 3WHO. Clinical management of severe acute" exact="respiratory" post="infection when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected;"/>
  <result pre="studyLancet Respir Med2020 3WHO. Clinical management of severe acute respiratory" exact="infection" post="when novel coronavirus (nCoV) infection is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected; 2020."/>
  <result pre="management of severe acute respiratory infection when novel coronavirus (nCoV)" exact="infection" post="is suspected. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected; 2020. 4HuangC.WangY.LiX.Clinical features of patients infected"/>
  <result pre="a reviewQJM2020 7HenterJ.I.HorneA.AricoM.HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosisPediatr" exact="Blood" post="Cancer48200712413116937360 8FardetL.GalicierL.LambotteO.Development and validation of the HScore, a score"/>
  <result pre="Care Med2020 10TianS.HuW.NiuL.LiuH.XuH.XiaoS.Y.Pulmonary pathology of early-phase 2019 Novel Coronavirus (COVID-19)" exact="pneumonia" post="in two patients with lung cancerJ Thorac Oncol2020 11JankaG.Hemophagocytic"/>
  <result pre="mild and severe cases of COVID-19Lancet Infect Dis2020 13BeutelG.WiesnerO.EderM.Virus-associated hemophagocytic" exact="syndrome" post="as a major contributor to death in patients with"/>
  <result pre="societyJ Allergy Clin Immunol Pract620181508151730201097 16ImashukuS.HibiS.OharaT.Effective control of Epstein-Barr virus-related" exact="hemophagocytic lymphohistiocytosis" post="with immunochemotherapy. Histiocyte SocietyBlood9319991869187410068659 17ImashukuS.KuriyamaK.SakaiR.Treatment of Epstein-Barr virus-associated hemophagocytic"/>
  <result pre="hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte SocietyBlood9319991869187410068659 17ImashukuS.KuriyamaK.SakaiR.Treatment of Epstein-Barr virus-associated" exact="hemophagocytic lymphohistiocytosis" post="(EBV-HLH) in young adults: a report from the HLH"/>
  <result pre="Epstein-Barr virus-associated hemophagocytic lymphohistiocytosisJ Clin Oncol1920012665267311352958 19HenterJ.I.Palmkvist-KaijserK.HolzgraefeB.BrycesonY.T.PalmerK.Cytotoxic therapy for severe" exact="swine flu" post="A/H1N1Lancet3762010211621168053 20AleemA.Al AmoudiS.Al-MashhadaniS.SiddiquiN.Haemophagocytic syndrome associated with hepatitis-B virus infection"/>
  <result pre="Oncol1920012665267311352958 19HenterJ.I.Palmkvist-KaijserK.HolzgraefeB.BrycesonY.T.PalmerK.Cytotoxic therapy for severe swine flu A/H1N1Lancet3762010211621168053 20AleemA.Al AmoudiS.Al-MashhadaniS.SiddiquiN.Haemophagocytic" exact="syndrome" post="associated with hepatitis-B virus infection responding to etoposideClin Lab"/>
  <result pre="severe swine flu A/H1N1Lancet3762010211621168053 20AleemA.Al AmoudiS.Al-MashhadaniS.SiddiquiN.Haemophagocytic syndrome associated with hepatitis-B" exact="virus infection" post="responding to etoposideClin Lab Haematol27200539539816307542 21TrottestamH.HorneA.AricoM.Chemoimmunotherapy for hemophagocytic lymphohistiocytosis:"/>
  <result pre="swine flu A/H1N1Lancet3762010211621168053 20AleemA.Al AmoudiS.Al-MashhadaniS.SiddiquiN.Haemophagocytic syndrome associated with hepatitis-B virus" exact="infection" post="responding to etoposideClin Lab Haematol27200539539816307542 21TrottestamH.HorneA.AricoM.Chemoimmunotherapy for hemophagocytic lymphohistiocytosis:"/>
 </snippets>
</snippetsTree>
